Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
32.84
+1.37 (4.35%)
Feb 2, 2026, 4:00 PM EST
SHE:301281 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 429.26 | 457.46 | 445.94 | 442.31 | 419.67 | 365.95 |
Other Revenue | 6.26 | 6.26 | 1.64 | 0.55 | 1.22 | 1.11 |
| 435.52 | 463.72 | 447.58 | 442.87 | 420.89 | 367.06 | |
Revenue Growth (YoY) | -0.52% | 3.60% | 1.06% | 5.22% | 14.67% | 18.02% |
Cost of Revenue | 210.85 | 266.76 | 240.86 | 264.82 | 246.14 | 187.25 |
Gross Profit | 224.67 | 196.96 | 206.73 | 178.04 | 174.75 | 179.81 |
Selling, General & Admin | 134.26 | 116.12 | 99.72 | 56.03 | 63.1 | 71.71 |
Research & Development | 48.96 | 35.82 | 43.86 | 26.97 | 24.43 | 27.84 |
Other Operating Expenses | 10.93 | 4.19 | 4.36 | 5.3 | 4.47 | 5.33 |
Operating Expenses | 195.3 | 156.42 | 148.25 | 89.14 | 92.11 | 103.96 |
Operating Income | 29.37 | 40.54 | 58.48 | 88.91 | 82.64 | 75.85 |
Interest Expense | -0.05 | -0.04 | - | - | - | -1.83 |
Interest & Investment Income | 10.24 | 15.4 | 15.97 | 1.33 | 0.96 | 0.11 |
Currency Exchange Gain (Loss) | -0.59 | -0.59 | 1.15 | 1.55 | -1.11 | -0.55 |
Other Non Operating Income (Expenses) | 5.51 | -2.03 | 0.09 | -0.32 | 0.05 | -0.38 |
EBT Excluding Unusual Items | 44.48 | 53.29 | 75.7 | 91.47 | 82.55 | 73.2 |
Gain (Loss) on Sale of Investments | 0.39 | 0.8 | 0.54 | - | - | - |
Gain (Loss) on Sale of Assets | -0.76 | -0.84 | 0.04 | 0.37 | -0.04 | -0.09 |
Asset Writedown | -1.84 | - | - | - | - | - |
Legal Settlements | -0.14 | -0.14 | - | - | - | - |
Other Unusual Items | 12.61 | 12.61 | 3.45 | 6.47 | 7.41 | 7.97 |
Pretax Income | 54.74 | 65.71 | 79.74 | 98.3 | 89.92 | 81.08 |
Income Tax Expense | 2.76 | 5.44 | 2.7 | 7.02 | 11.75 | 12.43 |
Net Income | 52.06 | 60.27 | 77.04 | 91.28 | 78.17 | 68.65 |
Net Income to Common | 52.06 | 60.27 | 77.04 | 91.28 | 78.17 | 68.65 |
Net Income Growth | 3.77% | -21.77% | -15.60% | 16.77% | 13.87% | 127.73% |
Shares Outstanding (Basic) | 108 | 108 | 101 | 81 | 81 | 81 |
Shares Outstanding (Diluted) | 108 | 108 | 101 | 81 | 81 | 81 |
Shares Change (YoY) | -0.45% | 6.18% | 24.38% | 0.53% | -0.47% | 0.34% |
EPS (Basic) | 0.48 | 0.56 | 0.76 | 1.12 | 0.96 | 0.84 |
EPS (Diluted) | 0.48 | 0.56 | 0.76 | 1.12 | 0.96 | 0.84 |
EPS Growth | 4.24% | -26.32% | -32.14% | 16.15% | 14.40% | 126.95% |
Free Cash Flow | -248.07 | -356.9 | -33.12 | 84.75 | 31.83 | 98.04 |
Free Cash Flow Per Share | -2.31 | -3.32 | -0.33 | 1.04 | 0.39 | 1.20 |
Dividend Per Share | 0.200 | 0.200 | 0.300 | 0.286 | - | - |
Dividend Growth | -33.33% | -33.33% | 5.00% | - | - | - |
Gross Margin | 51.59% | 42.47% | 46.19% | 40.20% | 41.52% | 48.99% |
Operating Margin | 6.74% | 8.74% | 13.06% | 20.08% | 19.63% | 20.66% |
Profit Margin | 11.95% | 13.00% | 17.21% | 20.61% | 18.57% | 18.70% |
Free Cash Flow Margin | -56.96% | -76.96% | -7.40% | 19.14% | 7.56% | 26.71% |
EBITDA | 68.43 | 83.84 | 107.43 | 122.54 | 109.5 | 101.2 |
EBITDA Margin | 15.71% | 18.08% | 24.00% | 27.67% | 26.02% | 27.57% |
D&A For EBITDA | 39.06 | 43.3 | 48.95 | 33.63 | 26.86 | 25.35 |
EBIT | 29.37 | 40.54 | 58.48 | 88.91 | 82.64 | 75.85 |
EBIT Margin | 6.74% | 8.74% | 13.06% | 20.08% | 19.63% | 20.66% |
Effective Tax Rate | 5.04% | 8.27% | 3.38% | 7.14% | 13.06% | 15.33% |
Revenue as Reported | 435.52 | 463.72 | 447.58 | 442.87 | 420.89 | 367.06 |
Advertising Expenses | - | 4.03 | 1.89 | - | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.